ALG-LungCancerRegistry (SAFRO2202)
Recruiting · NCT07161882 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characterize the epidemiological, clinical, pathological, molecular, and therapeutic features of patients diagnosed with lung cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and carcinoid tumors. Eligible participants are adults aged 18 years or older, diagnosed at the time of inclusion or within the previous 12 months, and fully managed in oncology or pulmonology departments. Data are collected during routine clinical care and recorded in a secure electronic case report form (eCRF). No protocol-mandated interventions or study-specific visits are required. The study plans to enroll approximately 1,500 patients per year over a 30-month period. Primary outcomes include demographic and clinical profiles, tumor histology, molecular markers, staging at diagnosis, and treatment strategies (surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy). Secondary outcomes include treatment-related toxicities, objective response rate (ORR), progression-free survival (PFS), time to treatment discontinuation (TTD), and overall survival (OS). The findings from this registry will provide real-world evidence to support national health planning, improve lung cancer management, and guide future clinical and public health initiatives in Algeria.
Who can take part
Inclusion criteria
- Age ≥ 18 years
- Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)
- Diagnosed at the time of inclusion or within the 12 previous months
- Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public/university hospitals
- Signed informed consent obtained
Exclusion criteria
- Prior enrollment in this study
- Participation in an interventional clinical trial
Where it is running
21 locations listed.
- Centre Pierre et Marie Curie - Algiers, Algiers Province, Algeria
- Chu Beni Messous - Isaad Hassani - Algiers, Algiers Province, Algeria
- CHU Mohamed Lamine Debaghine - Bab-el-Oued - Algiers, Algiers Province, Algeria
- Chu-Beni Messous - Isaad Hassani - Algiers, Algiers Province, Algeria
- EPH Rouiba - Algiers, Algiers Province, Algeria
- CLCC Annaba - Annaba, Annaba, Algeria
- CLCC Batna - Batna City, Batna, Algeria
- CAC-CHU Frantz Fanon - Blida, Blida Province, Algeria
- CHU- Hôpital Khelil Amrane - Béjaïa, Béjaia Province, Algeria
- CHU Dr Abdesselam Benbadis - Constantine, Constantine Province, Algeria
- EH Didouche Mourad - Constantine, Constantine Province, Algeria
- CLCC Draâ Ben Khedda - Tizi Ouzou, Draâ Ben Khedda, Algeria
- CAC-Laghouat - Laghouat, Laghouat Province, Algeria
- CAC Oran EL HASSI- EMIR ABDELKADER - Oran, Oran Province, Algeria
- CHU Dr. Benaouda Benzerdjeb - Oran, Oran Province, Algeria
- EHS 1er novembre - Oran, Oran Province, Algeria
- CAC- Ouargla - Ouargla, Ouargla Province, Algeria
- CAC El OUED - El Oued, Oued Souf, Algeria
- CAC- Sidi Bel Abbès - Sidi Bel Abbes, Sidi Bel Abbès Province, Algeria
- EPH- Sidi Ghiles - Tipasa, Sidi Ghiles, Algeria
- CAC-Sétif - Sétif, Sétif Province, Algeria